Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) CFO Keith A. Goldan sold 577 shares of the business’s stock in a transaction on Tuesday, June 13th. The stock was sold at an average price of $22.31, for a total value of $12,872.87. Following the transaction, the chief financial officer now owns 2,628 shares of the company’s […]
HealthCor Management L.P. lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 91.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,000 shares of the company’s stock after selling 789,240 shares during the period. Syndax Pharmaceuticals makes up about […]
Eversept Partners LP grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 33.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,620,713 shares of the company’s stock after purchasing an additional 409,279 shares during the quarter. Syndax Pharmaceuticals comprises 3.8% of […]
Nantahala Capital Management LLC reduced its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 30.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 975,705 shares of the company’s stock after selling 429,723 shares during the period. […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating)’s stock price traded up 8.6% during trading on Tuesday . The company traded as high as $22.67 and last traded at $22.53. 576,831 shares traded hands during trading, a decline of 32% from the average session volume of 842,487 shares. The stock had previously closed at $20.74. Analyst […]